Compare FTHM & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | SCNX |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Other Pharmaceuticals |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 24.8M |
| IPO Year | 2020 | 2020 |
| Metric | FTHM | SCNX |
|---|---|---|
| Price | $1.09 | $0.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 92.1K | ★ 1.7M |
| Earning Date | 11-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $421,612,000.00 | $653,391.00 |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 32.78 | ★ 207.88 |
| 52 Week Low | $0.65 | $0.46 |
| 52 Week High | $3.37 | $7.69 |
| Indicator | FTHM | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 42.55 |
| Support Level | $0.98 | $0.49 |
| Resistance Level | $1.11 | $0.60 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 31.03 | 10.11 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.